Stryker (NYSE:SYK) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Stryker (NYSE:SYK) released its quarterly earnings results on Thursday. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03), FiscalAI reports. Stryker had a net margin of 13.78% and a return on equity of 23.83%. The firm had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same quarter last year, the firm earned $3.19 earnings per share. The business’s revenue for the quarter was up 7.6% compared to the same quarter last year.

Here are the key takeaways from Stryker’s conference call:

• Hip and knee weakness pressured results: Stryker said the large-joint market has slowed to roughly 2.5% growth, citing affordability concerns, insurance-related preauthorization denials and softer international conditions. The company also acknowledged that cyber and SAP implementation disruptions hurt commercial execution and new-product adoption.
• Stryker lowered its 2026 outlook to 6.5%-7% organic sales growth and adjusted EPS of $14.80-$14.90, reflecting weaker hip and knee trends, lingering peripheral vascular supply constraints and a more conservative view of capital-equipment execution.
• Margins and cash generation remained strong: Third-quarter adjusted EPS rose 10.3% to $3.52, adjusted operating margin expanded 60 basis points to 26.2%, and year-to-date operating cash flow increased about 14% to $3.3 billion. The board also authorized an additional $3 billion for share repurchases.
• MedSurg and Neurotechnology grew 9.1%, led by Endoscopy, Medical and Vascular, while capital demand and the order book remained elevated. Stryker expects strong fourth-quarter contributions from Trauma and Extremities, Medical and Instruments, and highlighted upcoming growth drivers including AVS, new power-tool and endoscopy platforms, Mako products and the CMR Surgical robotics partnership.

Stryker Price Performance

NYSE:SYK traded down $20.19 during mid-day trading on Friday, reaching $291.56. The stock had a trading volume of 6,437,723 shares, compared to its average volume of 2,508,378. Stryker has a 12 month low of $267.00 and a 12 month high of $389.33. The stock has a 50-day simple moving average of $292.83 and a two-hundred day simple moving average of $324.51. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock has a market capitalization of $111.83 billion, a PE ratio of 31.05, a P/E/G ratio of 2.01 and a beta of 0.78.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a dividend of $0.88 per share. The ex-dividend date was Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SYK. Johnson Rice cut shares of Stryker to a “hold” rating in a research report on Friday. Wells Fargo & Company decreased their target price on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 9th. Argus set a $370.00 target price on shares of Stryker in a report on Thursday, July 9th. Citizens Jmp dropped their price target on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating for the company in a research report on Friday. Finally, Evercore set a $350.00 price target on Stryker in a research note on Monday, July 6th. Sixteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $355.84.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.